SCHEMBL1646689

SCHEMBL1646689

CCN(CC)c1ccc(C=CC(=O)CC(=O)C=Cc2ccc(N(CC)CC)cc2OC(=O)c2ccccc2)c(OC(=O)c2ccccc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.60
ALDH1A1 P00352 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NFE2L2 Q16236 1/20 0.45
MAPT P10636 6/20 0.44
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
APP P05067 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
POLB P06746 1/20 0.42
GFER P55789 1/20 0.42
HTT P42858 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
ESRRG P62508 1/20 0.40
PLK1 P53350 1/20 0.40
CNR2 P34972 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646687 1.00 BACE1 (0.60) BACE1ALDH1A1L3MBTL1NFE2L2MAPT
SCHEMBL1647350 0.92 BACE1 (0.74) BACE1
SCHEMBL1647352 0.92 BACE1 (0.74) BACE1
SCHEMBL1646997 0.87 ALDH1A1 (0.62) BACE1ALDH1A1L3MBTL1NFE2L2MAPT
SCHEMBL3218705 0.81 BACE1 (0.86) BACE1ALDH1A1L3MBTL1NFE2L2MAPT
SCHEMBL3218717 0.81 BACE1 (0.86) BACE1ALDH1A1L3MBTL1NFE2L2MAPT
SCHEMBL18962729 0.79 MAPT (0.54) ALDH1A1L3MBTL1NFE2L2MAPTKMT2A
SCHEMBL3211895 0.78 BACE1 (0.83) BACE1ALDH1A1L3MBTL1NFE2L2MAPT
SCHEMBL3211906 0.78 BACE1 (0.83) BACE1ALDH1A1L3MBTL1NFE2L2MAPT
SCHEMBL3208549 0.77 BACE1 (0.63) BACE1ALDH1A1L3MBTL1NFE2L2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962674-B2 Curcumin derivative TOKYO INSTITUTE OF TECHNOLOGY (JP) 2015-02-24 US disclosed
US-8552220-B2 Therapeutic agent for Alzheimer's disease TOKYO INSTITUTE OF TECHNOLOGY (JP) 2013-10-08 US disclosed
EP-2305629-A1 THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE Tokyo Institute of Technology (JP) 2011-04-06 EP disclosed
US-20100048901-A1 NOVEL CURCUMIN DERIVATIVE TOKYO INSTITUTE OF TECHNOLOGY (JP) 2010-02-25 US disclosed
EP-2123637-A1 NOVEL CURCUMIN DERIVATIVE Tokyo Institute of Technology (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048901-A1 NOVEL CURCUMIN DERIVATIVE BACE1, APP, BACE2 BACE1 1/4885ALDH1A1 253/4885L3MBTL1 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.